PB 33 of 2012
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012
(No.4)1
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under sections 84AF, 85, 85A, 88 and 101 of the National Health Act 1953.
Dated 4 May 2012
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
1 Name of Instrument
(1) This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012 (No. 4).
(2) This Instrument may also be cited as PB 33 of 2012.
2 Commencement
This Instrument commences on 1 June 2012.
3 Amendment of the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010)
Schedule 1 amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010).
Schedule 1 Amendments
[1] Schedule 1, entry for Amlodipine with Atorvastatin
substitute:
Amlodipine with Atorvastatin
Tablet 5 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium)
Oral
Cadatin 5/10
FZ
MP NP
C2449 C2450 C2451
30
5
Caduet 5/10
PF
MP NP
C2449 C2450 C2451
30
5
Tablet 5 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium)
Oral
Cadatin 5/20
FZ
MP NP
C2449 C2450 C2451
30
5
Caduet 5/20
PF
MP NP
C2449 C2450 C2451
30
5
Tablet 5 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium)
Oral
Cadatin 5/40
FZ
MP NP
C2449 C2450 C2451
30
5
Caduet 5/40
PF
MP NP
C2449 C2450 C2451
30
5
Tablet 5 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium)
Oral
Cadatin 5/80
FZ
MP NP
C2449 C2450 C2451
30
5
Caduet 5/80
PF
MP NP
C2449 C2450 C2451
30
5
Tablet 10 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium)
Oral
Cadatin 10/10
FZ
MP NP
C2449 C2450 C2451
30
5
Caduet 10/10
PF
MP NP
C2449 C2450 C2451
30
5
Tablet 10 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium)
Oral
Cadatin 10/20
FZ
MP NP
C2449 C2450 C2451
30
5
Caduet 10/20
PF
MP NP
C2449 C2450 C2451
30
5
Tablet 10 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium)
Oral
Cadatin 10/40
FZ
MP NP
C2449 C2450 C2451
30
5
Caduet 10/40
PF
MP NP
C2449 C2450 C2451
30
5
Tablet 10 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium)
Oral
Cadatin 10/80
FZ
MP NP
C2449 C2450 C2451
30
5
Caduet 10/80
PF
MP NP
C2449 C2450 C2451
30
5
[2] Schedule 1, entry for Amoxycillin
omit:
Sachet containing oral powder 3 g (as trihydrate)
Oral
Amoxil
GK
MP NP PDP
1
0
[3] Schedule 1, entry for Anastrozole in the form Tablet 1 mg
omit:
Anastrozole LW
TA
MP NP
C2213
30
5
[4] Schedule 1, entry for Atorvastatin
substitute:
Atorvastatin
Tablet 10 mg (as calcium)
Oral
APO-Atorvastatin
TX
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvachol
GM
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvastatin GH
GQ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvastatin Pfizer
FZ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvastatin Sandoz
SZ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Chem mart Atorvastatin
CH
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Lipitor
PF
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Lorstat 10
AF
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Terry White Chemists Atorvastatin
TW
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Torvastat 10
QA
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Trovas
RA
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
APO-Atorvastatin
TX
MP
C1540 C3047
P3047
30
11
Atorvachol
GM
MP
C1540 C3047
P3047
30
11
Atorvastatin GH
GQ
MP
C1540 C3047
P3047
30
11
Atorvastatin Pfizer
FZ
MP
C1540 C3047
P3047
30
11
Atorvastatin Sandoz
SZ
MP
C1540 C3047
P3047
30
11
Chem mart Atorvastatin
CH
MP
C1540 C3047
P3047
30
11
Lipitor
PF
MP
C1540 C3047
P3047
30
11
Lorstat 10
AF
MP
C1540 C3047
P3047
30
11
Terry White Chemists Atorvastatin
TW
MP
C1540 C3047
P3047
30
11
Torvastat 10
QA
MP
C1540 C3047
P3047
30
11
Trovas
RA
MP
C1540 C3047
P3047
30
11
Tablet 20 mg (as calcium)
Oral
APO-Atorvastatin
TX
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvachol
GM
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvastatin GH
GQ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvastatin Pfizer
FZ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvastatin Sandoz
SZ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Chem mart Atorvastatin
CH
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Lipitor
PF
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Lorstat 20
AF
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Terry White Chemists Atorvastatin
TW
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Torvastat 20
QA
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Trovas
RA
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
APO-Atorvastatin
TX
MP
C1540 C3047
P3047
30
11
Atorvachol
GM
MP
C1540 C3047
P3047
30
11
Atorvastatin GH
GQ
MP
C1540 C3047
P3047
30
11
Atorvastatin Pfizer
FZ
MP
C1540 C3047
P3047
30
11
Atorvastatin Sandoz
SZ
MP
C1540 C3047
P3047
30
11
Chem mart Atorvastatin
CH
MP
C1540 C3047
P3047
30
11
Lipitor
PF
MP
C1540 C3047
P3047
30
11
Lorstat 20
AF
MP
C1540 C3047
P3047
30
11
Terry White Chemists Atorvastatin
TW
MP
C1540 C3047
P3047
30
11
Torvastat 20
QA
MP
C1540 C3047
P3047
30
11
Trovas
RA
MP
C1540 C3047
P3047
30
11
Tablet 40 mg (as calcium)
Oral
APO-Atorvastatin
TX
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvachol
GM
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvastatin GH
GQ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvastatin Pfizer
FZ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvastatin Sandoz
SZ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Chem mart Atorvastatin
CH
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Lipitor
PF
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Lorstat 40
AF
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Terry White Chemists Atorvastatin
TW
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Torvastat 40
QA
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Trovas
RA
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
APO-Atorvastatin
TX
MP
C1540 C3047
P3047
30
11
Atorvachol
GM
MP
C1540 C3047
P3047
30
11
Atorvastatin GH
GQ
MP
C1540 C3047
P3047
30
11
Atorvastatin Pfizer
FZ
MP
C1540 C3047
P3047
30
11
Atorvastatin Sandoz
SZ
MP
C1540 C3047
P3047
30
11
Chem mart Atorvastatin
CH
MP
C1540 C3047
P3047
30
11
Lipitor
PF
MP
C1540 C3047
P3047
30
11
Lorstat 40
AF
MP
C1540 C3047
P3047
30
11
Terry White Chemists Atorvastatin
TW
MP
C1540 C3047
P3047
30
11
Torvastat 40
QA
MP
C1540 C3047
P3047
30
11
Trovas
RA
MP
C1540 C3047
P3047
30
11
Tablet 80 mg (as calcium)
Oral
APO-Atorvastatin
TX
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvachol
GM
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvastatin GH
GQ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvastatin Pfizer
FZ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Atorvastatin Sandoz
SZ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Chem mart Atorvastatin
CH
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Lipitor
PF
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Lorstat 80
AF
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Terry White Chemists Atorvastatin
TW
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Torvastat 80
QA
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
Trovas
RA
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
APO-Atorvastatin
TX
MP
C1540 C3047
P3047
30
11
Atorvachol
GM
MP
C1540 C3047
P3047
30
11
Atorvastatin GH
GQ
MP
C1540 C3047
P3047
30
11
Atorvastatin Pfizer
FZ
MP
C1540 C3047
P3047
30
11
Atorvastatin Sandoz
SZ
MP
C1540 C3047
P3047
30
11
Chem mart Atorvastatin
CH
MP
C1540 C3047
P3047
30
11
Lipitor
PF
MP
C1540 C3047
P3047
30
11
Lorstat 80
AF
MP
C1540 C3047
P3047
30
11
Terry White Chemists Atorvastatin
TW
MP
C1540 C3047
P3047
30
11
Torvastat 80
QA
MP
C1540 C3047
P3047
30
11
Trovas
RA
MP
C1540 C3047
P3047
30
11
[5] Schedule 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 2.5 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Biso 2.5
WQ
MP NP
C3234
28
5
[6] Schedule 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 5 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Biso 5
WQ
MP NP
C3234
28
5
[7] Schedule 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 10 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Biso 10
WQ
MP NP
C3234
28
5
[8] Schedule 1, entry for Carvedilol in the form Tablet 3.125 mg
(a) omit:
Dilasig 3.125
FM
MP NP
C1735 C3234
30
0
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Volirop 3.125
DO
MP NP
C1735 C3234
30
0
[9] Schedule 1, entry for Carvedilol in the form Tablet 6.25 mg
(a) omit:
Dilasig 6.25
FM
MP NP
C1735 C3234
60
5
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Volirop 6.25
DO
MP NP
C1735 C3234
60
5
[10] Schedule 1, entry for Carvedilol in the form Tablet 12.5 mg
(a) omit:
Dilasig 12.5
FM
MP NP
C1735 C3234
60
5
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Volirop 12.5
DO
MP NP
C1735 C3234
60
5
[11] Schedule 1, entry for Carvedilol in the form Tablet 25 mg
(a) omit:
Dilasig 25
FM
MP NP
C1735 C3234
60
5
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Volirop 25
DO
MP NP
C1735 C3234
60
5
[12] Schedule 1, entry for Cephazolin in each of the forms: Powder for injection 500 mg (as sodium); and Powder for injection 1 g (as sodium)
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Cefazolin-AFT
AE
MP NP
C1169 C1846 C1847 C3132
10
0
[13] Schedule 1, entry for Diltiazem in the form Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg
(a) omit from the column headed “Responsible Person” for the brand “Diltahexal CD”: SZ substitute: HX
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Diltiazem Sandoz CD
SZ
MP NP
30
5
[14] Schedule 1, entry for Fluconazole
omit:
Fluzole 50
QA
MP NP
C3613 C3614 C3615 C3616 C3617 C3618
28
5
[15] Schedule 1, entry for Fosinopril in each of the forms: Tablet containing fosinopril sodium 10 mg; and Tablet containing fosinopril sodium 20 mg
omit:
Fosinopril Sandoz
SZ
MP NP
30
5
[16] Schedule 1, entry for Fosinopril with Hydrochlorothiazide in the form Tablet containing fosinopril sodium 10 mg with hydrochlorothiazide 12.5 mg
omit:
Fosinopril/HCT Sandoz 10mg/12.5mg
SZ
MP NP
C3307
30
5
[17] Schedule 1, entry for Fosinopril with Hydrochlorothiazide in the form Tablet containing fosinopril sodium 20 mg with hydrochlorothiazide 12.5 mg
omit:
Fosinopril/HCT Sandoz 20mg/12.5mg
SZ
MP NP
C3307
30
5
[18] Schedule 1, entry for Gemcitabine in each of the forms: Powder for I.V. infusion 200 mg (as hydrochloride); and Powder for I.V. infusion 1 g (as hydrochloride)
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Gemaccord
WQ
MP
See Note 3
See Note 3
D
[19] Schedule 1, after entry for Glucose Indicator—Blood in the form Test strips, 100 (Accu-Chek Performa)
insert:
Test strips, 100 (Contour)
For external use
Contour
IK
MP NP
1
5
MP
P3035
1
11
[20] Schedule 1, entry for Irinotecan in each of the forms: I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL; and
I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Irinoccord
WQ
MP
C3184
See Note 3
See Note 3
D
[21] Schedule 1, entry for Lamotrigine in the form Tablet 25 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Torlemo DT 25
TA
MP NP
C1426
56
5
[22] Schedule 1, entry for Lamotrigine in the form Tablet 50 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Torlemo DT 50
TA
MP NP
C1426
56
5
[23] Schedule 1, entry for Lamotrigine in the form Tablet 100 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Torlemo DT 100
TA
MP NP
C1426
56
5
[24] Schedule 1, entry for Lamotrigine in the form Tablet 200 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Torlemo DT 200
TA
MP NP
C1426
56
5
[25] Schedule 1, entry for Mycophenolic Acid in the form Capsule containing mycophenolate mofetil 250 mg [Max Quantity 300; Number of Repeats 3]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Pharmacor Mycophenolate 250
CR
MP
C1765 C1766
300
3
[26] Schedule 1, entry for Mycophenolic Acid in the form Capsule containing mycophenolate mofetil 250 mg [Max Quantity 600; Number of Repeats 5]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Pharmacor Mycophenolate 250
CR
MP
See Note 1
C1650 C1651 C3355 C3356
600
5
C
[27] Schedule 1, entry for Oxaliplatin in each of the forms: Solution concentrate for I.V. infusion 50 mg in 10 mL; and Solution concentrate for I.V. infusion 100 mg in 20 mL
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Oxaliccord
WQ
MP
C3900 C3901 C3930 C3939
See Note 3
See Note 3
D
[28] Schedule 1, entry for Paroxetine in the form Tablet 20 mg (as hydrochloride)
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Roxet 20
DO
MP NP
C1211 C1241 C1862
30
5
[29] Schedule 1, entry for Paroxetine in the form Tablet 20 mg (as mesilate)
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Paroxetine Synthon
ZT
MP NP
C1211 C1241 C1862
30
5
[30] Schedule 1, entry for Simvastatin in the form Tablet 5 mg [Max Quantity 30; Number of Repeats 5]
(a) omit from the column headed “Responsible Person” for the brand “Simvahexal”: SZ substitute: HX
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Simvastatin Sandoz
SZ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
[31] Schedule 1, entry for Simvastatin in the form Tablet 5 mg [Max Quantity 30; Number of Repeats 11]
(a) omit from the column headed “Responsible Person” for the brand “Simvahexal”: SZ substitute: HX
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Simvastatin Sandoz
SZ
MP
C1540 C3047
P3047
30
11
[32] Schedule 1, entry for Simvastatin in the form Tablet 10 mg [Max Quantity 30; Number of Repeats 5]
(a) omit from the column headed “Responsible Person” for the brand “Simvahexal”: SZ substitute: HX
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Simvastatin Sandoz
SZ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
[33] Schedule 1, entry for Simvastatin in the form Tablet 10 mg [Max Quantity 30; Number of Repeats 11]
(a) omit from the column headed “Responsible Person” for the brand “Simvahexal”: SZ substitute: HX
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Simvastatin Sandoz
SZ
MP
C1540 C3047
P3047
30
11
[34] Schedule 1, entry for Simvastatin in the form Tablet 20 mg [Max Quantity 30; Number of Repeats 5]
(a) omit from the column headed “Responsible Person” for the brand “Simvahexal”: SZ substitute: HX
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Simvastatin Sandoz
SZ
MP
C1540 C3047
P1540
30
5
NP
C1540
30
5
[35] Schedule 1, entry for Simvastatin in the form Tablet 20 mg [Max Quantity 30; Number of Repeats 11]
(a) omit from the column headed “Responsible Person” for the brand “Simvahexal”: SZ substitute: HX
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Simvastatin Sandoz
SZ
MP
C1540 C3047
P3047
30
11
[36] Schedule 1, after entry for Tenofovir with emtricitabine and efavirenz
insert:
Tenofovir with Emtricitabine and Rilpivirine
Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg and rilpivirine 25 mg (as hydrochloride)
Oral
Eviplera
GI
MP
See Note 1
C3983 C3984 C3985 C3986
60
5
D
[37] Schedule 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Max Quantity 20; Number of Repeats 0]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Valaciclovir Pfizer
FZ
MP NP
C3622 C3623 C3624 C3631 C3632
P3632
20
0
[38] Schedule 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Max Quantity 30; Number of Repeats 5]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Valaciclovir Pfizer
FZ
MP NP
C3622 C3623 C3624 C3631 C3632
P3623 P3624
30
5
[39] Schedule 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Max Quantity 42; Number of Repeats 0]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
Valaciclovir Pfizer
FZ
MP NP
C3622 C3623 C3624 C3631 C3632
P3622 P3631
42
0
[40] Schedule 3, after details relevant to Responsible person code IA
insert:
IK
Medtronic Australasia Pty Ltd
47 001 162 661
[41] Schedule 4, Part 1, after entry for Tenofovir with emtricitabine and efavirenz
insert:
Tenofovir with Emtricitabine and Rilpivirine
C3983
Where the patient is receiving treatment at/from a private hospital
Initial treatment of human immunodeficiency virus (HIV) infection in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures
C3984
Where the patient is receiving treatment at/from a private hospital
Continuing treatment of human immunodeficiency virus (HIV) infection where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures
C3985
Where the patient is receiving treatment at/from a public hospital
Initial treatment of human immunodeficiency virus (HIV) infection in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease
Compliance with Written or Telephone Authority Required procedures Streamlined Authority Code 3985
C3986
Where the patient is receiving treatment at/from a public hospital
Continuing treatment of human immunodeficiency virus (HIV) infection where the patient has previously received PBS-subsidised therapy for HIV infection
Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3986
1
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.
See http://www.frli.gov.au.
